Claims
- 1. A compound having the formula:
- 2. (New) The compound, salt or hydrate of claim 1 wherein:
Ar5 is pyridine substituted with one or more halogens, or phenyl optionally substituted with one or more groups independently selected from the group consisting of halogen, or lower alkoxy; Ar6 is unsubstituted naphthyl; R17 is H or methyl; R18 is methyl; W is sulfur, sulfinyl, or sulfonyl; t is 0; u is 1.
- 3. The compound, salt or hydrate of claim 1 wherein:
Ar5 is indole, fluorene, or dibenzofuran optionally substituted with one or more groups independently selected from the group consisting of halogen, unsubstituted lower alkoxy, and lower alkyl substituted with one or more halogens; Ar6 is phenyl optionally substituted with one or more lower alkoxy; W is oxygen; t is 0; u is 2; R17 is hydrogen; and R18 is unsubstituted lower alkyl.
- 4. The compound, salt or hydrate of claim 1 wherein:
Ar5 is phenyl, napthyl, or carbozole, optionally substituted with one or more groups independently selected from the group consisting of halogen, lower alkyl, unsubstituted lower alkoxy, and lower alkyl substituted with one or more halogens; Ar6 is napthyl or phenyl optionally substituted with one or more lower alkoxy; t is 1; R16 is lower alkyl; R17 is hydrogen; R18 is lower alkyl; and W is N.
- 5. (New) A compound according to claim 2 selected from the group consisting of:
- 6. A compound according to claim 3 selected from the group consisting of:
- 7. A compound according to claim 4 selected from the group consisting of:
- 8. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 9. (New) A method of treating a patient comprising administering to said patient a therapeutically effective amount of one or more of compounds, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 10. (New) The method of claim 9 wherein said patient is suffering from a disease or disorder characterized by either or both of (1) abnormal calcium homeostasis and, (2) an abnormal amount of an intracellular or extracellular messenger whose production can be affected by calcium receptor activity.
- 11. (New) A method for modulating the PTH level in a patient comprising administering to said patient an effective amount of a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 12. (New) The method of claim 11 wherein said effective amount of said compound reduces said PTH level in a patient.
- 13. (New) The method of claim 12 wherein said patient has an abnormally high PTH level and effective amount of said compound reduces said PTH level in said patient to a degree sufficient to cause a decrease in plasma Ca2+.
- 14. (New) The method of claim 13, wherein administering said compound to said patient results in a PTH level in said patient equal to a level present in a normal individual.
- 15. (New) A method for modulating one or more Ca2+ receptors activities in a cell comprising administration to said cell one or more compounds, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 16. (New) The method of claim 15 wherein said cell is a parathyroid cell, a juxtaglomerular kidney cell, a proximal tubule kidney cell, a parafollicular thyroid cell, a bone osteoclast, a keratinocyte or a placental trophoblast.
- 17. (New) The method of claim 15 wherein the modulating one or more Ca2+ receptors activities in a cell treats or prevents a disorder selected from the group consisting of hyperparathyroidism, renal osteodystrophy, hypercalcemia malignancy, osteoporosis, Paget's disease and hypertension.
- 18. (New) The method of claim 17 wherein said hyperparathyroidism is primary hyperparathyroidism.
- 19. (New) The method of claim 17 wherein said hyperparathyroidism is secondary hyperparathyroidism.
- 20. (New) A pharmaceutical composition for treatment of primary and secondary hyperparathyroidism comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 21. (New) A pharmaceutical composition for treatment of renalosteodystrophy comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 22. (New) A pharmaceutical composition for treatment of hypercalcemia comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 23. (New) A pharmaceutical composition for treatment of hypercalcemia malignancy comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
- 86. (New) A pharmaceutical composition for treatment of osteoporosis comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula:
Priority Claims (3)
Number |
Date |
Country |
Kind |
9/107778 |
Apr 1997 |
JP |
|
8/350393 |
Dec 1996 |
JP |
|
8/178315 |
Jul 1996 |
JP |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of co-pending U.S. application Ser. No. 10/053,133, filed Jan. 17, 2002, which is a continuation of a co-pending U.S. application Ser. No. 09/214,552, filed Jan. 6, 1999, which claims priority to an International Application No. PCT/JP97/02358 filed on Jul. 8, 1997, which claims priority to Japanese Application Nos. 9/107778, filed Ap. 24, 1997; 8/350393, filed Dec. 27, 1996 and 8/178315, filed Jul. 8, 1996, all which are incorporated by reference herein.
Divisions (1)
|
Number |
Date |
Country |
Parent |
10053133 |
Jan 2002 |
US |
Child |
10326713 |
Dec 2002 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09214552 |
Jan 1999 |
US |
Child |
10053133 |
Jan 2002 |
US |